EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria

Wesley Dixon iD, Shaun Chandna iD, Jordan S Sack, Meagan Gray, Christina N Brown, Sampath Poreddy, Kai Ha, Michael R Schoech iD, Stephen D Zucker

Cancer Medicine · 2025

DOI: 10.1002/cam4.71428 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Wesley Dixon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation, Neoplasm Recurrence, Local. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many centers screen all recipients for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). This approach may add substantial burdens of cost, incidental findings, and, depending on the imaging modality, radiation and/or contrast‐induced complications. We created simple criteria to help clinicians identify low‐risk patients in whom post‐LT surveillance offers marginal utility.

Methods

Criteria were developed retrospectively using adults with HCC who underwent LT at the University of Cincinnati from 2000 to 2014. Low‐risk patients had none of the following at LT: (1) outside Milan criteria, (2) alpha‐fetoprotein ≥ 200 ng/mL, (3) prior hepatectomy with vascular invasion or unknown histology, and (4) any vascular invasion or > 3 lesions on explant, or extrahepatic extension noted intraoperatively. Criteria were retrospectively validated in adults transplanted for HCC at Mass General Brigham from 2015 to 2023 and prospectively assessed at Cincinnati where low‐risk patients received no post‐LT surveillance.

Results

Among 132 development cohort patients, 14 (10.6%) developed recurrent HCC at a median of 2.0 (range 0.1–9.7) years. Only 1 (1.1%) of the 91 (68.9%) patients deemed low‐risk by the proposed criteria developed recurrence compared to 13 (31.7%) of the high‐risk patients ( p < 0.001). In the validation cohort ( n = 188), recurrence occurred in 1 (0.9%) of 114 (60.6%) low‐risk and 16 (21.6%) high‐risk patients. In the prospective cohort ( n = 55), none of 42 (76.4%) low‐risk patients developed recurrence versus 3 (23.1%) high‐risk patients ( p = 0.011) after 8.0 (0.1–9.4) years of follow‐up. The criteria performed similarly to the RETREAT score 0 across cohorts ( n = 375) in identifying patients without recurrence as low‐risk (negative predictive value 99.2% vs. 97.1%) but required screening significantly fewer patients (34.1% vs. 81.9%).

Conclusions

These prospectively validated criteria offer clinicians a practical tool for easily and accurately determining which patients would benefit from surveillance for HCC recurrence after LT. Surveillance targeting only high‐risk patients could reduce the harms of excess screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalEarly Detection of CancerHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultProspective Studies

Stichwörter der Autor:innen

RETREATcancercirrhosisliver transplantpredictionrisk

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Division of Gastroenterology, Olive View-UCLA Medical Center, Sylmar, California, USA.
  • Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Gastrointestinal Associates, Inc., Jenkintown, Pennsylvania, USA.
  • Gastroenterology Division, Creighton University School of Medicine, Omaha, Nebraska, USA.
  • Gastrohealth, Cincinnati, Ohio, USA.

ORCID-Profile: Wesley Dixon, Shaun Chandna, Michael R Schoech

Zitieren

APA

Dixon, W., Chandna, S., Sack, J. S., Gray, M., Brown, C. N., Poreddy, S., Ha, K., Schoech, M. R., & Zucker, S. D. (2025). Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria. Cancer Medicine. https://doi.org/10.1002/cam4.71428

Vancouver

Dixon W, Chandna S, Sack JS, Gray M, Brown CN, Poreddy S, et al. Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria. Cancer Medicine. 2025. doi:10.1002/cam4.71428

BibTeX
@article{Dixon2025,
  author = {Dixon, Wesley and Chandna, Shaun and Sack, Jordan S and Gray, Meagan and Brown, Christina N and Poreddy, Sampath and Ha, Kai and Schoech, Michael R and Zucker, Stephen D},
  title = {Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71428}
}
Kostenlos starten →